Myasthenia gravis

37 trials 20 recruiting MedDRA PT
37 Registered trials
20 Recruiting
20 Unique sponsors
38 Unique IMPs
36 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 11
— ATC code not specified 18
A Gastroenterology (ATC A) 1
J Anti-infectives (ATC J) 5
N Neurology/Psychiatry (ATC N) 4
B Haematology (ATC B) 1
H Endocrinology (ATC H) 1
V Various (ATC V) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 8 substances
Vaccine 6 substances
Complement inhibitor (C5) 4 substances
FcRn antagonist 3 substances
Immunosuppressant 2 substances
Calcineurin inhibitor 2 substances
Immunoglobulin 2 substances
Antimetabolite 2 substances
Supportive / diluent 2 substances
Monoclonal antibody (chimeric) 1 substance
Corticosteroid 1 substance
Monoclonal antibody (immune, humanized) 1 substance
Receptor fusion protein 1 substance
Kinase inhibitor 1 substance
BTK inhibitor 1 substance
CAR-T cell therapy 1 substance
Phase III: 13 Phase II/III: 8 Phase II: 6 Phase I/II: 3 Phase I: 1 Phase I (Other): 1 Phase I (First in Human): 1 Other: 4

Filter these 37 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 37 trials

Phase III

13 trials
  • Argenx Commercial
    EFGARTIGIMOD ALFA
    2024-510932-36-00 7 countries 2021 n=42 Orphan
    Ended
  • Argenx Commercial
    EFGARTIGIMOD ALFA
    2024-511796-15-00 15 countries 2024 n=167 Orphan
    Ended
  • Cartesian Therapeutics Inc. Commercial
    DESCARTES-08
    2024-520355-25-00 3 countries 2025 n=29
    Recruiting
  • Deciphera Pharmaceuticals Inc. Commercial
    VIMSELTINIB
    2024-513624-42-00 7 countries 2021 n=79 Orphan
    Ended
  • Horizon Therapeutics Ireland Designated Activity Company Commercial
    IMP not specified
    2023-510006-40-00 5 countries 2021 n=125
    Ended
  • Janssen - Cilag International Commercial
    NIPOCALIMAB
    2023-504152-97-00 9 countries 2021 n=149
    Recruiting
  • Janssen - Cilag International Commercial
    NIPOCALIMAB
    2025-521130-28-00 4 countries n=29
    Pending
  • Merck Healthcare KGaA Commercial
    CLADRIBINE; RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E
    2023-507746-83-00 12 countries 2024 n=69
    Recruiting
  • Novartis Pharma AG Commercial
    REMIBRUTINIB
    2023-510026-32-00 8 countries 2025 n=131
    Recruiting
  • UCB Biopharma Commercial
    ZILUCOPLAN; ZILUCOPLAN SODIUM
    2022-502073-42-00 2 countries 2025 n=4
    Recruiting
  • UCB Biopharma Commercial
    ROZANOLIXIZUMAB
    2022-502075-34-00 2 countries 2024 n=7 Orphan
    Recruiting
  • UCB Biopharma Commercial
    ZILUCOPLAN SODIUM
    2023-508287-30-00 1 country 2024 n=6
    Ended
  • UCB Biopharma Commercial
    ZILUCOPLAN
    2024-512399-37-00 4 countries 2020 n=37
    Ended

Phase II/III

8 trials
  • Argenx Commercial
    EFGARTIGIMOD ALFA
    2023-506159-12-00 8 countries 2024 n=11 Orphan
    Recruiting
  • Argenx Commercial
    EFGARTIGIMOD ALFA
    2023-507379-23-00 9 countries 2022 n=19 Orphan
    Recruiting
  • Argenx Commercial
    EFGARTIGIMOD ALFA
    2024-513854-31-00 7 countries 2021 n=12 Orphan
    Recruiting
  • Janssen - Cilag International Commercial
    NIPOCALIMAB
    2022-502539-21-00 2 countries 2022 n=3
    Recruiting
  • Kyverna Therapeutics Inc. Commercial
    AZATHIOPRINE; CICLOSPORIN; ECULIZUMAB; HUMAN NORMAL IMMUNOGLOBULIN; KYV-101; METHOTREXATE SODIUM; MYCOPHENOLATE MOFETIL; PREDNISOLONE; RAVULIZUMAB; TACROLIMUS; ZILUCOPLAN
    2023-509892-17-00 1 country 2024 n=17 Orphan
    Recruiting
  • Kyverna Therapeutics Inc. Commercial
    KYV-101
    2024-511198-31-00 1 country 2026 n=30 Orphan
    Recruiting
  • UCB Biopharma Commercial
    ZILUCOPLAN; ZILUCOPLAN SODIUM
    2022-502072-23-00 2 countries 2025 n=4
    Recruiting
  • UCB Biopharma Commercial
    ROZANOLIXIZUMAB
    2022-502074-16-00 2 countries 2024 n=7 Orphan
    Recruiting

Phase II

6 trials
  • Amgen Inc. Commercial
    INEBILIZUMAB
    2025-520993-20-00 4 countries 2026 n=4
    Recruiting
  • Argenx Commercial
    EFGARTIGIMOD ALFA; EMPASIPRUBART
    2025-522492-28-00 7 countries 2026 n=52 Orphan
    Recruiting
  • Dianthus Therapeutics Inc. Commercial
    DNTH103; N. MENINGITIDIS GROUP C (STRAIN C11) POLYSACCHARIDE (DE-O-ACETYLATED) CONJUGATED TO TETANUS TOXOID, NEISSERIA MENINGITIDIS GROUP A POLYSACCHARIDE CONJUGATED TO TETANUS TOXOID CARRIER PROTEIN, NEISSERIA MENINGITIDIS GROUP W-135 POLYSACCHARIDE CONJUGATED TO TETANUS TOXOID CARRIER PROTEIN, NEISSERIA MENINGITIDIS GROUP Y POLYSACCHARIDE CONJUGATED TO TETANUS TOXOID CARRIER PROTEIN; RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NHBA FUSION PROTEIN PRODUCED IN E. COLI CELLS BY RECOMBINANT DNA TECHNOLOGY ADSORBED ON ALUMINIUM HYDROXIDE, RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NADA PROTEIN PRODUCED IN E. COLI CELLS BY RECOMBINANT DNA TECHNOLOGY ADSORBED ON ALUMINIUM HYDROXIDE, RECOMBINANT NEISSERIA MENINGITIDIS GROUP B FHBP FUSION PROTEIN PRODUCED IN E. COLI CELLS BY RECOMBINANT DNA TECHNOLOGY ADSORBED ON ALUMINIUM HYDROXIDE, OUTER MEMBRANE VESICLES (OMV) FROM NEISSERIA MENINGITIDIS GROUP B STRAIN NZ98/254 MEASURED AS AMOUNT OF TOTAL PROTEIN CONTAINING THE PORA P1.4 ADSORBED ON ALUMINIUM HYDROXIDE
    2024-512865-15-00 9 countries 2024 n=54
    Recruiting
  • NMD Pharma A/S Commercial
    NMD670
    2023-507539-40-00 7 countries 2024 n=59
    Recruiting
  • Vertex Pharmaceuticals Inc. Commercial
    POVETACICEPT
    2025-523950-15-01 1 country 2026 n=5
    Recruiting
  • Uniwersytet Medyczny W Lublinie Academic
    IMP not specified
    2024-517083-32-00 1 country 2021 n=200
    Ended

Phase I/II

3 trials
  • Aurinia Pharmaceuticals Inc. Commercial
    AUR200; SODIUM CHLORIDE
    2025-525127-27-00 1 country n=19
    Pending
  • Immunabs Inc. Commercial
    IM-101; MENINGOCOCCAL GROUP Y OLIGOSACCHARIDE CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE CRM197 PROTEIN, N. MENINGITIDIS GROUP C (STRAIN C11) POLYSACCHARIDE CONJUGATED CRM197, N. MENINGITIDIS GROUP A OLIGOSACCHARIDE CONJUGATED CRM197, N. MENINGITIDIS GROUP W135 OLIGOSACCHARIDE CONJUGATED CRM197; PERTUSSIS FILAMENTOUS HAEMAGGLUTININ ADSORBED ON ALUMINIUM HYDROXIDE, HYDRATED, PERTUSSIS TOXOID ADSORBED ON ALUMINIUM HYDROXIDE, HYDRATED, TETANUS TOXOID ADSORBED ON ALUMINIUM HYDROXIDE, HYDRATED, PERTUSSIS PERTACTIN ADSORBED ON ALUMINIUM HYDROXIDE, HYDRATED, HAEMOPHILUS TYPE B POLYSACCHARIDE CONJUGATED TO TETANUS TOXOID ADSORBED ON ALUMINIUM PHOSPHATE, HEPATITIS B SURFACE ANTIGEN (RDNA) ADSORBED ON ALUMINIUM PHOSPHATE [PRODUCED IN S. CEREVISAE CELLS BY RDNA], DIPHTHERIA TOXOID ADSORBED ON ALUMINIUM HYDROXIDE, HYDRATED, POLIOVIRUS (INACTIVATED) TYPE 1 (MAHONEY STRAIN) PRODUCED ON VERO CELLS, POLIOVIRUS (INACTIVATED) TYPE 2 (MEF-1 STRAIN) PRODUCED ON VERO CELLS, POLIOVIRUS (INACTIVATED) TYPE 3 (SAUKETT STRAIN) PRODUCED ON VERO CELLS; PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 1 CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 5 CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 3 CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6A CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 18C CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19A CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 7F CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 4 CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 14 CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9V CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6B CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23F CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19F CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE; RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NHBA FUSION PROTEIN PRODUCED IN E. COLI CELLS BY RECOMBINANT DNA TECHNOLOGY ADSORBED ON ALUMINIUM HYDROXIDE, RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NADA PROTEIN PRODUCED IN E. COLI CELLS BY RECOMBINANT DNA TECHNOLOGY ADSORBED ON ALUMINIUM HYDROXIDE, RECOMBINANT NEISSERIA MENINGITIDIS GROUP B FHBP FUSION PROTEIN PRODUCED IN E. COLI CELLS BY RECOMBINANT DNA TECHNOLOGY ADSORBED ON ALUMINIUM HYDROXIDE, OUTER MEMBRANE VESICLES (OMV) FROM NEISSERIA MENINGITIDIS GROUP B STRAIN NZ98/254 MEASURED AS AMOUNT OF TOTAL PROTEIN CONTAINING THE PORA P1.4 ADSORBED ON ALUMINIUM HYDROXIDE
    2025-522406-20-00 4 countries n=83
    Pending
  • Novartis Pharma AG Commercial
    HUMAN NORMAL IMMUNOGLOBULIN (IV); RAPCABTAGENE AUTOLEUCEL
    2024-513589-20-00 1 country 2025 n=3
    Recruiting

Phase I

1 trial
  • Tg Therapeutics Inc. Commercial
    UBLITUXIMAB
    2023-509555-13-00 1 country 2024 n=164
    Ended

Phase I (Other)

1 trial
  • Celgene Corp. Commercial
    IMP not specified
    2023-507820-22-00 4 countries 2024 n=56
    Halted

Phase I (First in Human)

1 trial
  • Toleranzia AB Commercial
    GLUCOSE; PREDNISOLONE; RECOMBINANT MUTATED EXTRACELLULAR DOMAIN OF THE HUMAN ACETYLCHOLINE RECEPTOR SUBUNIT ALPHA1
    2024-515627-10-00 3 countries n=42 Orphan
    Pending

Other

4 trials
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Argenx Commercial 6 Phase II/III, Phase II, Phase III 4
UCB Biopharma Commercial 6 Phase II/III, Phase III 4
Vianex S.A. Commercial 4 Other 0
Janssen - Cilag International Commercial 3 Phase II/III, Phase III 2
Kyverna Therapeutics Inc. Commercial 2 Phase II/III 2
Novartis Pharma AG Commercial 2 Phase III, Phase I/II 2
Tg Therapeutics Inc. Commercial 1 Phase I 0
Celgene Corp. Commercial 1 Phase I (Other) 0
Amgen Inc. Commercial 1 Phase II 1
Dianthus Therapeutics Inc. Commercial 1 Phase II 1
NMD Pharma A/S Commercial 1 Phase II 1
Vertex Pharmaceuticals Inc. Commercial 1 Phase II 1
Cartesian Therapeutics Inc. Commercial 1 Phase III 1
Deciphera Pharmaceuticals Inc. Commercial 1 Phase III 0
Horizon Therapeutics Ireland Designated Activity Company Commercial 1 Phase III 0
Merck Healthcare KGaA Commercial 1 Phase III 1
Toleranzia AB Commercial 1 Phase I (First in Human) 0
Aurinia Pharmaceuticals Inc. Commercial 1 Phase I/II 0
Immunabs Inc. Commercial 1 Phase I/II 0
Uniwersytet Medyczny W Lublinie Academic 1 Phase II 0
New trials by year
2020
1
2021
6
2022
2
2024
11
2025
7
2026
5
← All indication landscapes